SCHEMBL2277301

SCHEMBL2277301

CS(=O)(=O)C1CCN(CCC2CCN(c3ncc(Cl)cc3NC(=O)c3cccc(Cl)c3)CC2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 2/20 0.64
CACNA1I Q9P0X4 2/20 0.46
KCNH2 Q12809 2/20 0.46
ACHE P22303 2/20 0.40
GSK3B P49841 1/20 0.40
KMT2A Q03164 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
TNF P01375 1/20 0.40
THRB P10828 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
NOD2 Q9HC29 1/20 0.40
NOD1 Q9Y239 1/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SMO Q99835 1/20 0.38
USP2 O75604 2/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2221700 0.90 CXCR3 (0.68) CXCR3CACNA1IKCNH2ACHEGSK3B
SCHEMBL2269089 0.89 CXCR3 (0.69) CXCR3CACNA1IKCNH2KMT2ATDP1
SCHEMBL2271450 0.89 CXCR3 (0.69) CXCR3CACNA1IKCNH2ACHEGSK3B
SCHEMBL2268321 0.89 CXCR3 (0.66) CXCR3CACNA1IKCNH2ACHEGSK3B
SCHEMBL2268257 0.88 CXCR3 (0.70) CXCR3CACNA1IKCNH2KMT2AMAPT
SCHEMBL2267308 0.88 CXCR3 (0.70) CXCR3CACNA1IKCNH2KMT2AMAPT
SCHEMBL2272163 0.87 CXCR3 (0.68) CXCR3CACNA1IKCNH2ACHEGSK3B
SCHEMBL2223061 0.87 CXCR3 (0.68) CXCR3CACNA1IKCNH2KMT2ATDP1
SCHEMBL2272173 0.86 CXCR3 (0.65) CXCR3CACNA1IKCNH2KMT2ATDP1
SCHEMBL2223834 0.86 CXCR3 (0.65) CXCR3CACNA1IKCNH2ACHEGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US claimed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO claimed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885CACNA1I 2871/4885KCNH2 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.